Table of contents

Electronic pages

• Rational use of tocilizumab in COVID-19 (31 July, 2020)

  Siddharth Jain, Shefali Khanna Sharma
• Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma (31 July, 2020)

  Pier Leopoldo Capecchi, Pietro Enea Lazzerini
• Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma (31 July, 2020)

  Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, Antonio Abbate, Giustino Parruti
• Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Mathian et al

  (28 August, 2020)

  Quirin Notz, Patrick Meybohm, Peter Kranke, Dirk Weismann, Christopher Lotz, Marc Schmalzing
• Response to: ‘Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian et al’ by Notz et al

  (25 November, 2020)

  Alexis Mathian, Zahir Amoura
• Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ (21 September, 2020)

  Maria Vincenza Mastrolia, Rino Agostiniani, Chiara Azzari, Roberto Bernardini, Ugo Bottone, Giovanni Battista Calabri, Flavio Civitelli, Rita Consolini, Roberto Danieli, Rosalia Di Silvio, Susanna Falorni, Luigi Gagliardi, Salvatore Grosso, Marco Martini, Graziano Memmini, Diego Peroni, Marco Pezzati, Giovanni Suriano, Luca Tafi, Angelina Vaccaro, Pier Luigi Vasarri, Gabriele Simonini
• Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID19): a multicentre cohort’’ by Mastrolia et al

  (6 October, 2020)

  Charlotte Borocco, Marie Pouletty, Caroline Galeotti, Ulrich Meinzer, Albert Faye, Isabelle Koné-Paut, Naim Ouldali, Isabelle Melki
• Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti et al

  (9 September, 2020)

  Acer I-Hung Chen, Sheng-Chieh Lin, James Cheng-Chung Wei
• Response to: ‘Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti et al’ by Chen et al

  (9 September, 2020)

  Piero Ruscitti, Federico Bruno, Onorina Berardicurti, Chiara Acanfora, Viktoriya Pavlych, Pierpaolo Palumbo, Alessandro Conforti, Francesco Carubbi, Ilenia Di Cola, Paola Di Benedetto, Paola Cipriani, Davide Grassi, Carlo Masciocchi, Annamaria Iagnocco, Antonio Barile, Roberto Giacomelli
• Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases

  (7 September, 2020)

  Alessandro Giollo, Eugenia Bertoldo, Giovanni Adami, Adam J Cybulski, Angelo Fassio, Giovanni Orsolini, Luca Idolazzi, Davide Gatti, Ombretta viapiana, Maurizio Rossini
• Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases’ by Giollo et al

  (7 September, 2020)

  Kimme L Hyrich, Milena Gianfrancesco, Pedro M Machado, Jinoos Yazdany, Philip C Robinson
• Correspondence to ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study’ (11 November, 2020)

  Wenjie Zheng, Pui-Ying Leong, James Cheng-Chung Wei
• Response to ‘Correspondence on ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study’’ by Zheng et al

  (11 November, 2020)

  Dimitrios A Pappas, Gregory St John, Carol J Etzel, Stefano Fiore, Taylor Blachley, Toshio Kimura, Rajeshwari Punekar, Kelechi Emeanuru, Jeannie Choi, Susan Boklage, Joel M Kremer
• Correspondence on ‘Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort’ by Micheroli et al

  (15 September, 2020)

  Jin-Xian Huang, Pui-Ying Leong, James Cheng-Chung Wei
• Response to: ‘Correspondence on ‘Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort’ by Micheroli et al’ by Huang et al

  (15 September, 2020)

  Adrian Ciurea, Raphael Micheroli
• Correspondence on ‘Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study’ (21 September, 2020)

  Young Ho Lee
• Response to: ‘Correspondence on ‘Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study’ by Lee (21 September, 2020)

  Jiangwei Xia, Lin Xu, Ke-Qi Liu, Zhi-Min Ying, Shu-Yang Xie, Hou-Feng Zheng
• Short duration antibiotic therapy for native joint arthritis caused by Neisseria infection?

  (28 September, 2020)

  Maïlys Ducours, Samar El-Hout, Arnaud Desclaux, Hervé Dutronc, Thylbert Deltombe, Thomas Fauthoux, François Vercruysse, Marie Kostine, Charles Cazanave
• Response to: ‘Short duration antibiotic therapy for native joint arthritis cause by Neisseria infection?’ by Durcours et al

  (28 September, 2020)

  Ilker Uçkay, Konstantinos Vakalopoulos, Ergys Gjika
• Correspondence on ‘Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease’ (28 September, 2020)

  Yuri Muraviov, Ludmila Muraviova
• Response to: ‘Correspondence on ‘Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease’’ by Muraviov and Muraviova (28 September, 2020)

  Piero Ruscitti, Tanja A Stamm, Roberto Giacomelli
• Response to: ‘Correspondence on ‘Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease’’ by Muraviov and Muraviova (28 September, 2020)

  Claudia Kedor, Jan Zernicke, Eugen Feist
• Correspondence on ‘Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study’ (29 September, 2020)

  Po-Cheng Hung, Da-Hung Lin, Amy Ker, Chieh-Chun Yang, Hung-Wan Chien, James Cheng-Chung Wei
• Response to: ‘Correspondence on ‘Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study’’ by Hung et al

  (29 September, 2020)

  Hilde Berner Hammer, Lars Fridtjof Karoliussen, Lene Terslev, Espen A Haavardsholm, Tore K Kvien, Till Uhlig
• Severe polymyalgia-like symptoms secondary to anti-PD1 therapy successfully managed without discontinuing checkpoint inhibitor (6 May, 2020)

  Carlos Antonio Moura, Carlos Geraldo Moura
• Gender gap in rheumatology: speaker representation at annual conferences (13 May, 2020)

  Kanika Monga, Jean Liew